Direct-acting antivirals and chronic hepatitis C: towards elimination

@inproceedings{Franco2018DirectactingAA,
  title={Direct-acting antivirals and chronic hepatitis C: towards elimination},
  author={Ricardo Arango Franco and James W. Galbraith and Edgar Turner Overton and Michael S Saag},
  year={2018}
}
Hepatitis C virus (HCV) is a major cause of liver morbidity and mortality worldwide with increasing disease burden projected for the next several decades. The timely advent of direct-acting antivirals (DAAs) sparked significant public health responses aimed at HCV elimination by 2030. This review will focus on the implications of the DAAs in terms of medical progress, barriers to HCV elimination as a public health threat, and current gaps that will require further innovation. We utilized PubMed… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 192 REFERENCES

health sector strategies on viral hepatitis 2016-2021

WHO. Globa
  • Available from: https://www.who.int/hepatitis/strategy2016-2021/ ghss-hep/en/. [Last accessed on 28 Nov
  • 2018
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL

of deferring HCV treatment on liver-related events in HIV+ patients

CROI. Impac
  • Available from: http://www.croiconference.org/ sessions/impact-deferring-hcv-treatment-liver-related-events-hiv-patients. [Last accessed on 28 Nov
  • 2018
VIEW 12 EXCERPTS
HIGHLY INFLUENTIAL

Strategies to manage hepatitis C virus infection disease burden - volume 3.

  • Journal of viral hepatitis
  • 2015
VIEW 8 EXCERPTS
HIGHLY INFLUENTIAL

Historical epidemiology of hepatitis C virus (HCV) in selected countries.

  • Journal of viral hepatitis
  • 2014
VIEW 8 EXCERPTS
HIGHLY INFLUENTIAL